Literature DB >> 22026519

QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel.

Judith A Martin1, Anthony Campbell, Thomas Killip, Margaret Kotz, Mori J Krantz, Mary Jeanne Kreek, Brian A McCarroll, Davendra Mehta, J Thomas Payte, Barry Stimmel, Trusandra Taylor, Mark C P Haigney, Bonnie B Wilford.   

Abstract

In an effort to enhance patient safety in opioid treatment programs, the Substance Abuse and Mental Health Saervices Administration convened a multi-disciplinary Expert Panel on the Cardiac Effects of Methadone. Panel members (Appendix A) reviewed the literature, regulatory actions, professional guidances, and opioid treatment program experiences regarding adverse cardiac events associated with methadone. The Panel concluded that, to the extent possible, every opioid treatment program should have a universal Cardiac Risk Management Plan (incorporating clinical assessment, electrocardiogram assessment, risk stratification, and prevention of drug interactions) for all patients and should strongly consider patient-specific risk minimization strategies (such as careful patient monitoring, obtaining electrocardiograms as indicated by a particular patient's risk profile, and adjusting the methadone dose as needed) for patients with identified risk factors for adverse cardiac events. The Panel also suggested specific modifications to informed consent documents, patient education, staff education, and methadone protocols.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22026519      PMCID: PMC4078896          DOI: 10.1080/10550887.2011.610710

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  88 in total

1.  Methadone-related Torsades de Pointes in a sickle cell patient treated for chronic pain.

Authors:  Brian O Porter; Patrick J Coyne; Wally R Smith
Journal:  Am J Hematol       Date:  2005-04       Impact factor: 10.047

2.  Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study.

Authors:  Einat Peles; Gershon Bodner; Mary Jeanne Kreek; Vera Rados; Miriam Adelson
Journal:  Addiction       Date:  2007-02       Impact factor: 6.526

3.  Anti-cholinesterase activity of 1-alpha-acetylmethadol: relationship to bradycardia.

Authors:  D C Eikenburg; J L Stickney
Journal:  Gen Pharmacol       Date:  1979

Review 4.  Clinical safety profile of sotalol in patients with arrhythmias.

Authors:  L F Soyka; C Wirtz; R B Spangenberg
Journal:  Am J Cardiol       Date:  1990-01-02       Impact factor: 2.778

Review 5.  Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.

Authors:  Fabrizio De Ponti; Elisabetta Poluzzi; Andrea Cavalli; Maurizio Recanatini; Nicola Montanaro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  A twist on torsade: a prolonged QT interval on methadone.

Authors:  Patricia Lamont; Susan C Hunt
Journal:  J Gen Intern Med       Date:  2006-11       Impact factor: 5.128

7.  Methadone-induced torsade de pointes in a patient with normal baseline QT interval.

Authors:  Ammar Almehmi; Amer M Malas; Mohammed Yousufuddin; J Gregory Rosencrance
Journal:  W V Med J       Date:  2004 Jul-Aug

8.  Calcium channel blockade by certain opioids.

Authors:  D E Seyler; J L Borowitz; R P Maickel
Journal:  Fundam Appl Toxicol       Date:  1983 Nov-Dec

9.  Chronic methadone therapy complicated by torsades de pointes: a case report.

Authors:  Laura Pimentel; Douglas Mayo
Journal:  J Emerg Med       Date:  2007-11-26       Impact factor: 1.484

Review 10.  hERG potassium channels and cardiac arrhythmia.

Authors:  Michael C Sanguinetti; Martin Tristani-Firouzi
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

View more
  20 in total

1.  ACMT Position Statement: The Use of Methadone as an Analgesic.

Authors: 
Journal:  J Med Toxicol       Date:  2016-06

Review 2.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

3.  Effectiveness of A-CRA/ACC in treating adolescents with cannabis-use disorders.

Authors:  Elizabeth L McGarvey; MaGuadalupe Leon-Verdin; Karen Bloomfield; Sharon Wood; Esther Winters; Jennifer Smith
Journal:  Community Ment Health J       Date:  2012-11-16

Review 4.  Caring for patients with opioid use disorder in the hospital.

Authors:  Joseph H Donroe; Stephen R Holt; Jeanette M Tetrault
Journal:  CMAJ       Date:  2016-09-19       Impact factor: 8.262

5.  Medications for Opioid Use Disorder: A Guide for Physicians.

Authors:  Naazia Azhar; Ravikumar Chockalingam; Asad Azhar
Journal:  Mo Med       Date:  2020 Jan-Feb

Review 6.  Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.

Authors:  Tae Woo Park; Peter D Friedmann
Journal:  R I Med J (2013)       Date:  2014-10-01

7.  Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.

Authors:  David P Kao; Mark C P Haigney; Philip S Mehler; Mori J Krantz
Journal:  Addiction       Date:  2015-09       Impact factor: 6.526

8.  Methadone and the QTc Interval: Paucity of Clinically Significant Factors in a Retrospective Cohort.

Authors:  Gavin Bart; Zachary Wyman; Qi Wang; James S Hodges; Rehan Karim; Bradley A Bart
Journal:  J Addict Med       Date:  2017 Nov/Dec       Impact factor: 3.702

Review 9.  Medical and psychological risks and consequences of long-term opioid therapy in women.

Authors:  Beth D Darnall; Brett R Stacey; Roger Chou
Journal:  Pain Med       Date:  2012-08-20       Impact factor: 3.750

10.  Trends in reporting methadone-associated cardiac arrhythmia, 1997-2011: an analysis of registry data.

Authors:  David Kao; Becki Bucher Bartelson; Vaishali Khatri; Richard Dart; Philip S Mehler; David Katz; Mori J Krantz
Journal:  Ann Intern Med       Date:  2013-05-21       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.